Currently, Briostatin cancer drugs are being tested for phase L and phase II cancer in accordance with the program of the American National Institute of Clinical Trials. Brisostatin-1 is a natural class of chemical that is toxic to cells (cytotoxic). Drugs for treating cancer of Briostatin are produced by the bacterium Candidatus endobugula sertula and are found in the marine mshanzone Bugula neritina. The iron-like bacterium C. endobugula sertula produces chemical briostatin during the larval stage of bryozoa development. Young larvae of bryozoans are covered with this compound, allowing young larvae to be unpleasant and unpleasant for predators.
Bryozoan Bugula neritina is a small aquatic animal less than 1 mm long that forms colonies similar to corals and sponges. Briozoan colonies can be of different plant types, like moss, branch or tree, to gelatinous masses. Bryozoans are water supplies. There are more than 5,000 species of bryozoans in the world with approximately 50 species of freshwater species. More noticeable 130 species of bryozoans, as a rule, are unpleasant animal hulls, moorings, moorings and docks. Some freshwater species form large jelly-like masses, which tend to clog up industrial water intakes. Bryozoin Bugula neritina is found in the Pacific Ocean off the coast of California, in the Gulf of Mexico and in Aomori Bay in Japan.
The best source of cytotoxic chemical briostatin I was discovered in 1968 by owners of Bugula neritina bryozoans. It was found that leukemia meningitis had active anti-leukemia activity. He showed perspective against lung cancer, prostate cancer, non-Hodgkin's lymphoma, and possibly pancreatic cancer. Anti-cancer drugs Briostatin act synergistically with other cancer drugs and are powerful activators of protein kinase C.
Currently, more than 20 species of bryostatin have been identified from the mammal Bugula neritina. It currently consumes about 14 tons of Briozoanin Bugula neritina to produce 1 ounce of Bryostatin. To synthesize briostatin, the chemical formula C47H68O17 with a molecular weight of 905.033, it takes more than 50 steps in the laboratory.
The effective mechanism of bryostatin is its unique ability to activate the cellular signaling enzyme Protein Kinase C (PKC), which leads to the inhibition of the growth of tumor cells and causes the death of tumor cells. PKC is an enzyme that is important for controlling biochemical reactions in the cell. Drugs for treating Briostatin cancer have been associated with the initiation of an immune response, regulation of cell growth activity, as well as in learning and memory. Cancer cells under rapid growth and need controlled growth so that the cells cannot damage the body.
Since it is a PKC promoter, bryostatin is considered to help improve memory and, in particular, to combat Alzheimer's disease. Briostatin has been shown to increase learning speed in rats. About 40 clinical trials of Phase 1 and Phase 2 are currently underway for the use of drugs for the treatment of lung cancer and many cancer patients and in patients with Alzheimer's disease. Clinical trials that were far from cancer, such as: kidney, stomach, chest, prostate, lungs, esophagus, head and neck, ovary, fallopian tube, cervix, multiple myeloma, and leukemia, to name a few.
Currently, Albert Einstein University Yeshiva University is conducting metastatic studies of pancreatic phase II cancer using Briostatin-1 and Paclitaxel. The results of this study and other cancer studies can be found in the program of the American National Institute for Clinical Trials.
